Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2016

01-02-2016 | Perspective

Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?

Authors: William M. Tierney, MD, Eric M. Meslin, PhD, Kurt Kroenke, MD

Published in: Journal of General Internal Medicine | Issue 2/2016

Login to get access

Abstract

Pharmaceutical and device manufacturers fund more than half of the medical research in the U.S. Research funding by for-profit companies has increased over the past 20 years, while federal funding has declined. Research funding from for-profit medical companies is seen as tainted by many academicians because of potential biases and prior misbehavior by both investigators and companies. Yet NIH is encouraging partnerships between the public and private sectors to enhance scientific discovery. There are instances, such as methods for improving drug adherence and post-marketing drug surveillance, where the interests of academician researchers and industry could be aligned. We provide examples of ethically performed industry-funded research and a set of principles and benchmarks for ethically credible academic–industry partnerships that could allow academic researchers, for-profit companies, and the public to benefit.
Literature
1.
go back to reference Moses H III, Matheson DHM, Cairns-Smith S, George BP, Palisch C, Dorsey R. The anatomy of medical research: US and international comparisons. JAMA. 2015;313:174–89.CrossRefPubMed Moses H III, Matheson DHM, Cairns-Smith S, George BP, Palisch C, Dorsey R. The anatomy of medical research: US and international comparisons. JAMA. 2015;313:174–89.CrossRefPubMed
5.
go back to reference Patent and Trademark Law Amendments Act of 1980, Pub. L. No. 96–517, 94 Stat. 3015, 69331 (1980) (codified as amended at 35 U.S.C. ch. 30 (2011)). Patent and Trademark Law Amendments Act of 1980, Pub. L. No. 96–517, 94 Stat. 3015, 69331 (1980) (codified as amended at 35 U.S.C. ch. 30 (2011)).
6.
go back to reference Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010); Sec. 6002: Transparency Reports and Reporting of Physician Ownership or Investment Interests (codified as 42 U.S.C.A. § 1320a-7h). Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010); Sec. 6002: Transparency Reports and Reporting of Physician Ownership or Investment Interests (codified as 42 U.S.C.A. § 1320a-7h).
9.
go back to reference Farwell WR, Stump TE, Wang J, Tafesse E, L’Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19:1200–5.PubMedCentralCrossRefPubMed Farwell WR, Stump TE, Wang J, Tafesse E, L’Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19:1200–5.PubMedCentralCrossRefPubMed
10.
go back to reference Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491–2.CrossRefPubMed Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491–2.CrossRefPubMed
11.
go back to reference Jain SH, Rosenblatt M, Duke J. Is big data the new frontier for academic-industry collaboration? JAMA. 2014;311:2171–2.CrossRefPubMed Jain SH, Rosenblatt M, Duke J. Is big data the new frontier for academic-industry collaboration? JAMA. 2014;311:2171–2.CrossRefPubMed
12.
go back to reference Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171–3.PubMedCentralCrossRefPubMed Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171–3.PubMedCentralCrossRefPubMed
13.
go back to reference Godlee F, Smith J, Marcovitch H. Wakefield’s article linking MR vaccine and autism was fraudulent. BMJ. 2011;342:c7452.CrossRefPubMed Godlee F, Smith J, Marcovitch H. Wakefield’s article linking MR vaccine and autism was fraudulent. BMJ. 2011;342:c7452.CrossRefPubMed
15.
16.
go back to reference Olsen AK, Whalen MD. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. Drug Saf. 2009;32:805–10.CrossRefPubMed Olsen AK, Whalen MD. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. Drug Saf. 2009;32:805–10.CrossRefPubMed
17.
go back to reference Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345–59.CrossRefPubMed Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345–59.CrossRefPubMed
20.
go back to reference McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMed McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMed
21.
go back to reference Newman JC, Feldman R. Copyright and open access at the bedside. N Engl J Med. 2011;365(26):2447–9.CrossRefPubMed Newman JC, Feldman R. Copyright and open access at the bedside. N Engl J Med. 2011;365(26):2447–9.CrossRefPubMed
22.
go back to reference Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:iii. ix-xi, 1–193. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:iii. ix-xi, 1–193.
23.
go back to reference Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173:580–1.CrossRefPubMed Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173:580–1.CrossRefPubMed
25.
go back to reference Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results by academic life scientists: evidence from a national survey of faculty. JAMA. 1997;277:1224–8.CrossRefPubMed Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results by academic life scientists: evidence from a national survey of faculty. JAMA. 1997;277:1224–8.CrossRefPubMed
27.
go back to reference Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–55.CrossRefPubMed Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–55.CrossRefPubMed
28.
go back to reference Krimsky S. Do financial conflicts of interest bias research? An inquiry into the “funding effect” hypothesis. Sci Technol Hum Values. 2013;38:566–87.CrossRef Krimsky S. Do financial conflicts of interest bias research? An inquiry into the “funding effect” hypothesis. Sci Technol Hum Values. 2013;38:566–87.CrossRef
29.
go back to reference Sterne JA. Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev. 2013;12:ED000076.PubMed Sterne JA. Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev. 2013;12:ED000076.PubMed
30.
go back to reference Carpenter WT Jr, Koenig JI, Bilbe G, Bischoff S. At issue: a model for academic/industry collaboration. Schizophr Bull. 2004;30:997–1004.CrossRefPubMed Carpenter WT Jr, Koenig JI, Bilbe G, Bischoff S. At issue: a model for academic/industry collaboration. Schizophr Bull. 2004;30:997–1004.CrossRefPubMed
32.
go back to reference Rosenbaum L. Beyond moral outrage – Weighing trade-offs of COI regulation. N Engl J Med. 2015;372:2064–8.CrossRefPubMed Rosenbaum L. Beyond moral outrage – Weighing trade-offs of COI regulation. N Engl J Med. 2015;372:2064–8.CrossRefPubMed
33.
go back to reference Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ. 2015;350:h2942.CrossRefPubMed Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ. 2015;350:h2942.CrossRefPubMed
Metadata
Title
Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?
Authors
William M. Tierney, MD
Eric M. Meslin, PhD
Kurt Kroenke, MD
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 2/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3495-z

Other articles of this Issue 2/2016

Journal of General Internal Medicine 2/2016 Go to the issue

Clinical Practice: Clinical Images

Scimitar Syndrome

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.